<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552122</url>
  </required_header>
  <id_info>
    <org_study_id>0822-050</org_study_id>
    <nct_id>NCT01552122</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density, Tolerability, and Safety in the Treatment of Postmenopausal Women With Osteoporosis Previously Treated With Alendronate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral
      density in osteoporotic postmenopausal women who were previously treated with alendronate.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Bone Mineral Density (BMD) of the Femoral Neck</measure>
    <time_frame>Baseline and Month 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in BMD of the Lumbar Spine, Total Hip, and Trochanter</measure>
    <time_frame>Baseline and Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Odanacatib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Odanacatib</intervention_name>
    <description>Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months</description>
    <arm_group_label>Odanacatib</arm_group_label>
    <other_name>MK-0822</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.</description>
    <arm_group_label>Alendronate</arm_group_label>
    <other_name>Alendronate Sodium</other_name>
    <other_name>Fosamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (odanacatib)</intervention_name>
    <description>One compressed tablet administered orally, once-a-week, for 24 months.</description>
    <arm_group_label>Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol (Vitamin D3)</intervention_name>
    <description>Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.</description>
    <arm_group_label>Odanacatib</arm_group_label>
    <arm_group_label>Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.</description>
    <arm_group_label>Odanacatib</arm_group_label>
    <arm_group_label>Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (alendronate)</intervention_name>
    <description>One compressed tablet administered orally, once-a-week, for 24 months.</description>
    <arm_group_label>Odanacatib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good general health, and postmenopausal for at least 5 years or more

          -  Diagnosed with postmenopausal osteoporosis

          -  Currently taking alendronate for at least 3 years or more for the treatment of
             osteoporosis

          -  One hip free of orthopedic hardware (ie, total hip device, hip pin); anatomy is
             suitable to undergo a dual-emission X-ray absorptiometry (DXA) scan (ie, bone mineral
             density scan)

          -  Agrees to not to use any other medications for the treatment of osteoporosis except
             those provided to the participant during the study

        Exclusion Criteria:

          -  Evidence of metabolic bone disorder

          -  History of malignancy (cancer) for 5 years or less

          -  Active thyroid disease that cannot be managed with medication

          -  Severe renal insufficiency (kidney disease), myocardial infarction, unstable angina,
             stroke or revascularization, untreated malabsorption syndrome, and/or osteonecrosis of
             the jaw, or anticipates undergoing a major dental procedure (e.g. dental extraction or
             implantation)

          -  Use, misuse, abuse, and/or addiction of illicit drugs and/or recent history

        (within the last year) of drug or alcohol abuse or dependence

          -  Use of estrogen with or without progestin and/or raloxifene (ie, Evista®) or tamoxifen
             (ie, Nolvadex®, Tamofen®)

          -  Use of any oral bisphosphonate therapy other than alendronate; intravenous
             bisphosphonates (zoledronate, ibandronate, pamidronate); any form of calcitonin other
             than intranasal; anabolic steroids; and/or Strontium-containing products (ie,
             Osteovalin™)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

